Xact Kapitalforvaltning’s Novavax NVAX Stock Holding History

Xact Kapitalforvaltning’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,010	Closed	-$184K	–	1509
2018 Q4	$184K	Sell	5,010 -25	-0.5%	-$969	﹤0.01%	1447
2018 Q3	$189K	Buy	5,035 +1,445	+40%	+$40.7K	﹤0.01%	1529
2018 Q2	$96K	Buy	3,590 +765	+27%	+$25.9K	﹤0.01%	1577
2018 Q1	$119K	Buy	+2,825	New	+$113K	﹤0.01%	1517

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Xact Kapitalforvaltning's NVAX Position: Q1 2019 in Review

Xact Kapitalforvaltning sold out of Novavax (NVAX) in Q1 2019, closing a stake of 5,010 shares — an estimated $184K sold.

Xact Kapitalforvaltning first reported a position in NVAX in Q1 2018 and held it in 4 quarters. The position peaked at $189K in Q3 2018. 140 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

Xact Kapitalforvaltning reported no remaining Novavax position as of Q1 2019 after selling out during the quarter.
Xact Kapitalforvaltning sold 5,010 Novavax shares in Q1 2019, an estimated $184K.
Xact Kapitalforvaltning first reported a position in Novavax in Q1 2018 and held it in 4 quarters.
Xact Kapitalforvaltning's Novavax position peaked at $189K in Q3 2018.
140 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2019, filed 10 May 2019.